Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06731413 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 1 to 2v6
  2. Eligibility criteria expanded, about 10 wordsv5
  3. Site contact updatedv4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 15, 2025 to Feb 11, 2025
    • Site details revised
    v3
  5. Start date: Dec 15, 2024 to Mar 15, 2025
    • Primary completion date: Apr 30, 2030 to Jul 30, 2030
    • Study completion date: Apr 30, 2033 to Jul 30, 2033
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluate frequency of adverse events that lead to chemotherapy discontinuation in vulnerable older adults with recurrent/metastatic PD-L1 TPS\<50% NSCLC patients who receive reduced dose chemotherapy in combination with immunotherapy.
Trial Details
NCT Number NCT06731413
Lead Sponsor Virginia Commonwealth University
Conditions
(from sponsor)		 Non-Small Cell Lung Cancer, NSCLC, Advanced Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov